FeesSafety
Pluang+

HUTCHMED presents promising preclinical data for HMPL-A830, a novel cancer drug targeting EGFR and KRAS mutations.

Market News
19 Nov 2026, 02:00 WIB
GlobeNewsWire
View Source
Bullish
HUTCHMED presents promising preclinical data for HMPL-A830, a novel cancer drug targeting EGFR and KRAS mutations.

HUTCHMED announced preclinical results for HMPL-A830, a new drug candidate combining an EGFR antibody with a potent KRAS inhibitor, designed to overcome resistance and toxicity in cancer treatment. The drug showed strong activity against multiple KRAS mutations and EGFR-positive tumors in lab and animal studies, outperforming existing treatments. HMPL-A830 is currently in early clinical trials, with HUTCHMED managing Phase I development and GSK handling later stages globally outside China. This dual-targeting approach aims to improve efficacy and safety in cancers driven by KRAS and EGFR, addressing significant unmet medical needs.

GSK, which is involved in the global development of HMPL-A830, trades at USD 49.20 on Pluang as of Nov 19, 2026 07:11 WIB. The stock experienced a 2.40% decline in the last day. Investors on Pluang show full buying interest with 100% buy orders and no sell orders at this time.

More News (GSK)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App